Inflammation, ageing and cancer

Mechanisms of Ageing and Development

Volumn 130, Issue 1-2, 2009, Pages 40-45

  Vasto, Sonya ^a,c   Carruba, Giuseppe ^a,b   Lio, Domenico ^a   Colonna Romano, Giuseppina ^a   Di Bona, Danilo ^a,c,d   Candore, Giuseppina ^a   Caruso, Calogero ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b Ospedale Civico ARNAS   (Italy)

^c Medicina Trasfusionale ed Immunoematologia   (Italy)

^d CNR   (Italy)

Author keywords

Ageing; Cancer; Genetics; Inflammation; Longevity

Indexed keywords

AUTACOID;

AGING; ARTICLE; BURKITT LYMPHOMA; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC DISEASE; DISEASE ASSOCIATION; DISEASE CONTROL; EPSTEIN BARR VIRUS; GENE FREQUENCY; GENETIC MARKER; HELICOBACTER PYLORI; HUMAN; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; LEUKOCYTE; LONGEVITY; MICROENVIRONMENT; MOLECULAR EVOLUTION; NASOPHARYNX CARCINOMA; NEOPLASM; PATHOGENESIS; PRIORITY JOURNAL; STOMACH CARCINOMA;

AGED; AGED, 80 AND OVER; AGING; HUMANS; INCIDENCE; INFLAMMATION; NEOPLASMS;

EID: 58149337527     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2008.06.003     Document Type: Article

References (90)

1. Achyut B.R., Ghoshal U.C., Moorchung N., and Mittal B. Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum. Immunol. 68 (2007) 901-907
2. Allavena P., Garlanda C., Borrello M.G., Sica A., and Mantovani A. Pathways connecting inflammation and cancer. Curr. Opin. Genet. Dev. 18 (2008) 3-10
3. American Cancer Society. Cancer Facts and Figures 2007 (2007), American Cancer Society, Atlanta
4. Badal V., Menendez S., Coomber D., and Lane D.P. Regulation of the p14ARF promoter by DNA methylation. Cell Cycle 1 (2008) 112-119
5. Balistreri C.R., Candore G., Colonna-Romano G., Lio D., Caruso M., Hoffmann E., Franceschi C., and Caruso C. Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 292 (2004) 2339-2340
6. Balistreri C.R., Candore G., Listì F., Fazio T., Gangi S., Incalcaterra E., Caruso M., Vecchi M.L., Lio D., and Caruso C. Role of TLR4 polymorphisms in inflammatory responses: implications for unsuccessful aging. Ann. N. Y. Acad. Sci. 1119 (2007) 203-207
7. Bonafè M., Barbi C., Storci G., Salvioli S., Capri M., Olivieri F., Valensin S., Monti D., Gonos E.S., De Benedictis G., and Franceschi C. What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. Exp. Gerontol. 37 (2002) 1263-1271
8. Bruunsgaard H. The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality. Dan. Med. Bull. 53 (2006) 285-309
9. Campisi J. Suppressing cancer: the importance of being senescent. Science 309 (2005) 886-887
10. Candore G., Balistreri C.R., Colonna-Romano G., Lio D., and Caruso C. Major histocompatibility complex and sporadic Alzheimer's disease: a critical reappraisal. Exp. Gerontol. 39 (2004) 645-652
11. Candore G., Colonna-Romano G., Balistreri C.R., Di Carlo D., Grimaldi M.P., Listi F., Nuzzo D., Vasto S., Lio D., and Caruso C. Biology of longevity: role of the innate immune system. Rejuvenation Res. 9 (2006) 1
12. Candore G., Balistreri C.R., Listì F., Grimaldi M.P., Vasto S., Colonna-Romano G., Franceschi C., Lio D., Caselli G., and Caruso C. Immunogenetics, gender, and longevity. Ann. N. Y. Acad. Sci. 1089 (2006) 516-537
13. Capri M., Salvioli S., Monti D., Caruso C., Candore G., Vasto S., Olivieri F., Marchegiani F., Sansoni P., Baggio G., Mari D., Passarino G., De Benedictis G., and Franceschi C. Human longevity within an evolutionary perspective: the peculiar paradigm of a post-reproductive genetics. Exp. Gerontol. 43 (2008) 53-60
14. Cardelli M., Cavallone L., Marchegiani F., Oliveri F., Dato S., Montesanto A., Lescai F., Lisa R., De Benedictis G., and Franceschi C. A genetic-demographic approach reveals male-specific association between survival and tumor necrosis factor (a/g)-308 polymorphism. J. Gerontol. A Biol. Sci. Med. Sci. 63 (2008) 454-460
15. Caruso C., Lio D., Cavallone L., and Franceschi C. Aging, longevity, inflammation, and cancer. Ann. N. Y. Acad. Sci. 1028 (2004) 1-13
16. Caruso C., Candore G., Colonna-Romano G., Lio D., and Franceschi C. Inflammation and life-span. Science 307 (2005) 208-209
17. Caruso C., Balistreri C.R., Crivello A., Forte G.I., GrimaldiI M.P., Listì F., Scola L., Vasto S., and Candore G. The genetics of innate immunity and inflammation in ageing, age-related diseases and longevity. Pawelec G. Immunosenescence (2007), Landes Bioscience and Springer Science, Austin, TX 78701, United States. 978-0-387-76840-3 pp. 154-173
18. Chen Y.C., Giovannucci E., Kraft P., Lazarus R., and Hunter D.J. Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1982-1989
19. Chen R., Alvero A.B., Silasi D.A., Steffensen K.D., and Mor G. Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene 27 (2008) 225-233
20. Cheng I., Liu X., Plummer S.J., Krumroy L.M., Casey G., and Witte J.S. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br. J. Cancer 97 (2007) 557-561
21. Cohen T., Nahari D., Cerem L.W., Neufeld G., and Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271 (1996) 736-741
22. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
23. Culig Z., Steiner H., Bartsch G., and Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J. Cell Biochem. 95 (2005) 497-505
24. Danforth K.N., Rodriguez C., Hayes R.B., Sakoda L.C., Huang W.Y., Yu K., Calle E.E., Jacobs E.J., Chen B.E., Andriole G.L., Figueroa J.D., Yeager M., Platz E.A., Michaud D.S., Chanock S.J., Thun M.J., and Hsing A.W. TNF polymorphisms and prostate cancer risk. Prostate 68 (2008) 400-407
25. Deans C., Rose-Zerilli M., Wigmore S., Ross J., Howell M., Jackson A., Grimble R., and Fearon K. Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann. Surg. Oncol. 14 (2007) 329-339
26. De Martinis M., Franceschi C., Monti D., and Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 579 (2005) 2035-2039
27. De Martinis M., Franceschi C., Monti D., and Ginaldi L. Inflammation markers predicting frailty and mortality in the elderly. Exp. Mol. Pathol. 80 (2006) 219-227
28. DePinho R.A. The age of cancer. Nature 408 (2000) 248-254
29. Deyrup A.T. Epstein-Barr virus-associated epithelial and mesenchymal neoplasms. Hum. Pathol. 39 (2008) 473-483
30. Dummer W., Becker J.C., Schwaaf A., Leverkus M., Moll T., and Bröcker E.B. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 5 (1995) 67-68
31. Edwards J., Mukherjee R., Munro A.F., Wells A.C., Almushatat A., and Bartlett J.M. Her2 and COX2 expression in human prostate cancer. Eur. J. Cancer 40 (2004) 50-55
32. Ershler W.B., and Keller E.T. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 51 (2000) 245-270
33. Finkel T., Serrano M., and Blasco M.A. The common biology of cancer and ageing. Nature 448 (2007) 767-774
34. Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann. Clin. Lab. Sci. 31 (2001) 325
35. Fox J.G., and Wang T.C. Inflammation, atrophy, and gastric cancer. J. Clin. Invest. 117 (2007) 60-69
36. Franceschi C., Capri M., Monti D., Giunta S., Olivieri F., Sevini F., Panourgia M.P., Invidia L., Celani L., Scurti M., Cevenini E., Castellani G.C., and Salvioli S. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 128 (2007) 92-105
37. Franceschi C., Motta L., Motta M., Malaguarnera M., Capri M., Vasto S., Candore G., and Caruso C. IMUSCE. The extreme longevity: the state of the art in Italy. Exp. Gerontol. 43 (2008) 45-52
38. Garrity-Park M.M., Loftus Jr. E.V., Bryant S.C., Sandborn W.J., and Smyrk T.C. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am. J. Gastroenterol. 103 (2008) 407-415
39. Heikkilä K., Ebrahim S., and Lawlor D.A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur. J. Cancer 44 (2008) 937-945
40. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374 (2003) 1-20
41. Hong D.S., Angelo L.S., and Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110 (2007) 1911-1928
42. Hou L., Grillo P., Zhu Z.Z., Lissowska J., Yeager M., Zatonski W., Zhu G., Baccarelli A., Chanock S.J., Fraumeni Jr. J.F., and Chow W.H. COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res. 27 (2007) 4243-4247
43. Hutchins D., and Steel C.M. Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int. J. Cancer 58 (1994) 80-84
44. International Agency for Research on Cancer. Globocan 2000. IARC 2002.
45. Kamimura D., Ishihara K., and Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149 (2003) 1-38
46. Kirkwood T.B. p53 and ageing: too much of a good thing?. Bioessays 24 (2002) 577-579
47. Krabbe K.S., Pedersen M., and Bruunsgaard H. Inflammatory mediators in the elderly. Exp. Gerontol. 39 (2004) 687-699
48. Licastro F., Candore G., Lio D., Porcellini E., Colonna-Romano G., Franceschi C., and Caruso C. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun. Ageing 2 (2005) 8
49. Lin W.W., and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117 (2007) 1175-1183
50. Litovkin K.V., Domenyuk V.P., Bubnov V.V., and Zaporozhan V.N. Interleukin-6-174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp. Oncol. 29 (2007) 295-298
51. Mantovani A., Romero P., Palucka A.K., and Marincola F.M. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371 (2008) 771-783
52. Matsuda M., Salazar F., Petersson M., Masucci G., Hansson J., Pisa P., Zhang Q.J., Masucci M.G., and Kiessling R. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 180 (1994) 2371-2376
53. Michaud D.S., Daugherty S.E., Berndt S.I., Platz E.A., Yeager M., Crawford E.D., Hsing A., Huang W.Y., and Hayes R.B. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res. 66 (2006) 4525-4530
54. Miyaishi O., Ando F., Matsuzawa K., Kanawa R., and Isobe K. Cancer incidence in old age. Mech. Ageing Dev. 117 (2000) 47-55
55. Mocchegiani E., Giacconi R., Costarelli L., Muti E., Cipriano C., Tesei S., Pierpaoli S., Giuli C., Papa R., Marcellini F., Gasparini N., Pierandrei R., Piacenza F., Mariani E., Monti D., Dedoussis G., Kanoni S., Herbein G., Fulop T., Rink L., Jajte J., and Malavolta M. Zinc deficiency and IL-6-174G/C polymorphism in old people from different European countries: effect of zinc supplementation. ZINCAGE study. Exp. Gerontol. 43 (2008) 433-444
56. Mocellin S., and Nitti D. TNF and cancer: the two sides of the coin. Front Biosci. 13 (2008) 2774-2783
57. Moons L.M., Kuipers E.J., Rygiel A.M., Groothuismink A.Z., Geldof H., Bode W.A., Krishnadath K.K., Bergman J.J., van Vliet A.H., Siersema P.D., and Kusters J.G. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am. J. Gastroenterol. 102 (2007) 2373-2379
58. Naylor M.S., Stamp G.W.H., Foulkes W.D., Eccles D., and Balkwill F.R. Tumor necrosis factor and its receptors in human ovarian cancer: potential role in disease progression. J. Clin. Invest. 91 (1993) 2194-2206
59. Perwez Hussain S., Hofseth L.J., and Harris C.C. Radical causes of cancer. Nat. Rev. Cancer 3 (2003) 276-285
60. Ridker P.M. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr. Rev. 65 (2007) S253-S259
61. Salazar-Onfray F., Lopez M.N., and Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 18 (2007) 171-182
62. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., and Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol. 52 (2002) 168-174
63. Serrano M., and Blasco M.A. Putting the stress on senescence. Curr. Opin. Cell Biol. 13 (2001) 748-753
64. Serrano M., and Blasco M.A. Cancer and ageing: convergent and divergent mechanisms. Nat. Rev. Mol. Cell Biol. 8 (2007) 715-722
65. Shacter E., and Weitzman S.A. Chronic inflammation and cancer. Oncology 16 (2002) 217-226
66. Shen J., Gammon M.D., Terry M.B., Teitelbaum S.L., Neugut A.I., and Santella R.M. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 8 (2006) R71
67. Sica A., Allavena P., and Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. (2008) (Epub ahead of print)
68. Slattery M.L., Wolff R.K., Herrick J.S., Caan B.J., and Potter J.D. IL6 genotypes and colon and rectal cancer. Cancer Causes Control 18 (2007) 1095-1105
69. Smith D.W. Cancer mortality at very old age. Cancer 77 (1996) 1367-1372
70. Smith W.I., Dewitt D.I., and Garavito R.M. Cyclooxygenases: structural, cellular and molecular biology. Annu. Rev. Biochem. 69 (2006) 145-182
71. Stearns M.E., Rhim J., and Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin. Cancer Res. 5 (1999) 189-196
72. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24 (2003) 96-102
73. Sun Q., Liu Q., Zheng Y., and Cao X. Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol. Immunol. 45 (2008) 2929-2936
74. Sun J., Wiklund F., Hsu F.C., Bälter K., Zheng S.L., Johansson J.E., Chang B., Liu W., Li T., Turner A.R., Li L., Li G., Adami H.O., Isaacs W.B., Xu J., and Grönberg H. Interactions of sequence variants in interleukin-1 receptor-associated kinase 4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 480-485
75. Szlosarek P.W., and Balkwill F.R. Tumor necrosis factor α: a potential target for the therapy of solid tumors. Lancet Oncol. 4 (2003) 565-573
76. Terry D.F., Wilcox M.A., McCormick M.A., Pennington J.Y., Schoenhofen E.A., Andersen S.L., and Perls T.T. Lower all-cause, cardiovascular, and cancer mortality in centenarians' offspring. J. Am. Geriatr. Soc. 52 (2004) 2074-2076
77. Trichopoulos D., Psaltopoulou T., Orfanos P., Trichopoulou A., and Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 381-384
78. Troen B.R. The biology of aging. Mt. Sinai J. Med. 70 (2003) 3-22
79. Turini M.E., and DuBois R.N. Cyclooxygenase-2: a therapeutic target. Annu. Rev. Med. 53 (2002) 35-57
80. Upadhyay R., Jain M., Kumar S., Ghoshal U.C., and Mittal B. Association of interleukin-6 (-174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin. Immunol. (2008) (Epub ahead of print)
81. Ueda N., Maehara Y., Tajima O., Tabata S., Wakabayashi K., and Kono S. Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study. Cancer Sci. 99 (2008) 576-581
82. Vairaktaris E., Yapijakis C., Serefoglou Z., Derka S., Vassiliou S., Nkenke E., Vylliotis A., Spyridonidou S., Neukam F.W., Schlegel K.A., and Patsouris E. The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res. 28 (2008) 309-314
83. Vairaktaris E., Yiannopoulos A., Vylliotis A., Yapijakis C., Derka S., Vassiliou S., Nkenke E., Serefoglou Z., Ragos V., Tsigris C., Vorris E., Critselis E., Avgoustidis D., Neukam F.W., and Patsouris E. Strong association of interleukin-6-174 G>C promoter polymorphism with increased risk of oral cancer. Int. J. Biol. Markers 21 (2006) 246-250
84. Vasto S., Candore G., Balistreri C.R., Caruso M., Colonna-Romano G., Grimaldi M.P., Listi F., Nuzzo D., Lio D., and Caruso C. Inflammatory networks in ageing, age-related diseases and longevity. Mech. Ageing Dev. 128 (2007) 83-91
85. Vasto S., Candore G., Listì F., Balistreri C.R., Colonna-Romano G., Malavolta M., Lio D., Nuzzo D., Mocchegiani E., Di Bona D., and Caruso C. Inflammation, genes and zinc in Alzheimer's disease. Brain Res. Rev. (2008) (Epub ahead of print)
86. Williams G.M. Antitumor necrosis factor-alpha therapy and potential cancer inhibition. Eur. J. Cancer Prev. 17 (2008) 169-177
87. Witz I.P. Yin-yang activities and vicious cycles in the tumor microenvironment. Cancer Res. 68 (2008) 9-13
88. Zhang J., Dou C., Song Y., Ji C., Gu S., Xie Y., and Mao Y. Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis. J. Hum. Genet. 53 (2008) 479-489
89. Zheng S.L., Augustsson-Balter K., Chang B., Hedelin M., Li L., Adami H.O., Bensen J., Li G., Johnasson J.E., Turner A.R., Adams T.S., Meyers D.A., Isaacs W.B., Xu J., and Grönberg H. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res. 64 (2004) 2918-2922
90. Zhu J., Quyyumi A.A., Norman J.E., Csako G., Waclawiw M.A., Shearer G.M., and Epstein S.E. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am. J. Cardiol. 85 (2000) 140-146